Abstracts tagged "Ixekizumab"

Abstract Number: 1347 • ACR Convergence 2021
Ixekizumab Efficacy in Patients with Psoriatic Arthritis Presenting with Symptoms Indicative of Axial Involvement
Atul Deodhar¹, Dafna Gladman², Rebecca Bolce³, David Sandoval³, So Young Park³, Soyi Liu-Leage⁴, Peter Nash⁵ and Denis Poddubnyy⁶, ¹Oregon Health & Science University, Portland, OR, ²Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ³Eli Lilly and Company, Indianapolis, IN, ⁴Eli Lilly and Company, Neuilly sur Seine, France, ⁵Griffith University, Brisbane, Australia, ⁶Department of Rheumatology, Charité – Universitätsmedizin, Berlin, Germany
Background/Purpose: Many patients with psoriatic arthritis (PsA) experience back pain and stiffness indicative of axial involvement [1]. The prevalence of axial involvement varies between 25-70%…
Abstract Number: 1828 • ACR Convergence 2021
Safety Profile of Ixekizumab for the Treatment of Psoriatic Arthritis and Axial Spondyloarthritis up to 3 Years: An Updated Integrated Safety Analysis
Sergio Schwartzman¹, Atul Deodhar², Bernard Combe³, Ana Accioly⁴, Andris Kronbergs⁴, Boris Janos⁵, Danting Zhu⁴, David Sandoval Calderon⁴, Proton Rahman⁶ and Denis Poddubnyy⁷, ¹Self Employed 72nd Street Medical Associates, Scarsdale, NY, ²Oregon Health & Science University, Portland, OR, ³CHU Montpellier Montpellier University, Montpellier, France, ⁴Eli Lilly and Company, Indianapolis, IN, ⁵Eli Lilly, Calgary, AB, Canada, ⁶Department of Medicine, Eastern Health and Memorial University of Newfoundland, St John's, NL, Canada, ⁷Department of Rheumatology, Charité – Universitätsmedizin, Berlin, Germany
Background/Purpose: Ixekizumab (IXE) is a high-affinity monoclonal antibody that selectively targets IL-17A approved for the treatment of psoriasis, psoriatic arthritis (PsA), active ankylosing spondylitis (AS)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].